BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim DG, Choi Y, Lee Y, Lim S, Kong J, Song J, Roh Y, Harmalkar DS, Lee K, Goo JI, Cho HY, Mushtaq AU, Lee J, Park SH, Kim D, Min BS, Lee KY, Jeon YH, Lee S, Lee K, Kim S. AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis. Nat Commun 2022;13:2572. [PMID: 35546148 DOI: 10.1038/s41467-022-30149-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee B, Kim DG, Lee A, Kim YM, Cui L, Kim S, Choi I. Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug. Journal of Enzyme Inhibition and Medicinal Chemistry 2023;38:51-66. [DOI: 10.1080/14756366.2022.2135510] [Reference Citation Analysis]
2 Lee Y, Yoon SB, Hong H, Kim HY, Jung D, Moon BS, Park WK, Lee S, Kwon H, Park J, Cho H. Discovery of GSK3β Inhibitors through In Silico Prediction-and-Experiment Cycling Strategy, and Biological Evaluation. Molecules 2022;27:3825. [PMID: 35744952 DOI: 10.3390/molecules27123825] [Reference Citation Analysis]